[Risk/Benefit Communication: International Developments and Prospects for the Future].

Area of Science:

• Pharmacology
• Health Communication
• Patient Safety

Background:

• Adverse drug reactions remain a significant health concern despite high pharmaceutical expectations.
• Insufficient risk communication among stakeholders (healthcare professionals, agencies, pharmaceutical companies) contributes to this problem.
• Japan's risk management plan system, introduced four years ago, faces challenges in effective utilization of patient and HCP materials.

Purpose of the Study:

• To highlight the importance of risk communication in pharmacotherapy.
• To review research activities on risk communication in Japan and internationally.
• To emphasize the need for improved drug information provision for safe medication use.

Main Methods:

• Review of existing literature and research activities on risk communication.
• Analysis of the role of stakeholders in communicating drug risks and benefits.
• Examination of patient-centered information systems developed internationally.

Main Results:

• Risk communication is identified as a critical factor in managing pharmaceutical risks and benefits.
• International models incorporating patient perspectives in risk/benefit communication have been developed.
• The effectiveness of current risk communication strategies and materials remains difficult to ascertain.

Conclusions:

• Enhanced risk communication strategies are essential for improving patient safety and pharmacotherapy outcomes.
• Pharmacologists and pharmacists have a key role to play in advancing risk communication research and practice.
• Further research is needed to ensure effective utilization of drug information and risk management plans.